Bahaa Abu Bakr, MD
Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1285879775
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 198 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 198 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$614
- Insulet Corporation$510
- Dexcom, Inc.$257
- Ascensia Diabetes Care US Inc.$217
- Amgen$209
- Sanofi-aventis U.S. LLC$207
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,069100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $614 |
| Insulet Corporation | 47 | $510 |
| Dexcom, Inc. | 8 | $257 |
| Ascensia Diabetes Care US Inc. | 11 | $217 |
| Amgen(2 entities) | 13 | $209 |
| Sanofi-aventis U.S. LLC | 14 | $207 |
| Lilly USA, LLC | 8 | $156 |
| Cequr Corporation | 2 | $148 |
| Boehringer Ingelheim | 8 | $128 |
| AbbVie | 8 | $123 |
| Corcept Therapeutics | 5 | $93 |
| Radius Health, Inc. | 2 | $62 |
| Mannkind Corporation | 2 | $52 |
| Antares Pharma, Inc. | 2 | $37 |
| Abbott | 2 | $35 |
| Medtronic | 2 | $33 |
| AstraZeneca | 2 | $27 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Organon | 1 | $16 |
| Bayer | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
| Merck | 1 | $11 |
How this compares
$3,069 in reported general payments places this provider in the 60th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $189,466 |
| MounjaroTirzepatide | 63 | $103,332 |
| Tresiba Flextouch U-100Insulin Degludec | 126 | $90,738 |
| JardianceEmpagliflozin | 83 | $83,035 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 86 | $69,924 |
| JanuviaSitagliptin Phosphate | 50 | $50,768 |
| TradjentaLinagliptin | 49 | $42,964 |
| TrulicityDulaglutide | 39 | $38,654 |
| FarxigaDapagliflozin Propanediol | 36 | $34,870 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $30,603 |
| Novolog FlexpenInsulin Aspart | 144 | $29,318 |
| Victoza 3-PakLiraglutide | 15 | $22,927 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,339 |
| Bydureon BciseExenatide Microspheres | 24 | $19,419 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $18,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $614 | $189,466148 claims |
| Lilly USA, LLCMounjaro, Trulicity | $156 | $141,986102 claims |
| Boehringer IngelheimJardiance, Tradjenta | $128 | $125,999132 claims |
| MerckJanuvia | $11 | $50,76850 claims |
| AstraZenecaFarxiga | $27 | $34,87036 claims |
| AbbVieSynthroid | $123 | $13,615180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Topeka
- Susan BrianTopeka$9K
- Alan WynneTopeka$8K
- Christine UyTopeka$7K
- Jeffrey FajardoTopeka$2K
- Su Ah BaeTopeka$2K
- Francisco CorreaTopeka$2K
- Noor AddasiTopeka$741
- Dana AwadTopeka$340
- Vidita DivanTopeka$276
- Kaitlin DitchTopeka$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.